62 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants … expected in the second quarter; greater than 90% of participants dosed –
– Prior Phase 2 MARCH Part B chronic hepatitis B data demonstrated
8-K
VIR
Vir Biotechnology Inc
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
is prioritizing investment in the clinical execution of its chronic hepatitis delta and chronic hepatitis B programs, as well as on broadening
8-K
EX-99.1
aezc n0irawk
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
1sobta7 un
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
ylcheeas4 0pzj
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
noex qwxz0gdlxl
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
rv67a03sr5g04m65q
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
5g6kqeydrx0tkgd4oj6
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
wh5c7kj
25 Mar 22
Other Events
4:10pm
8-K
EX-99.1
d1lg8w91bd6vn3tmx
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm